{
  "id": 446356,
  "title": "Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe",
  "url": "https://urgent.news/2026/08/10/samsung-bioepis-launches-opuviztm-aflibercept-40-mg-ml-pre-filled",
  "topic": "world",
  "section": "World",
  "published": "2026-08-10T07:30:06.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=274484"
  },
  "original_language": "en",
  "account": "Samsung Bioepis has launched OPUVIZ™, a 40 mg/mL pre-filled syringe (PFS) of the biosimilar aflibercept, throughout Europe. The company's Vice President and Head of Europe, Antonio Rito, expressed satisfaction with the introduction of this new format, highlighting its convenience for injections and improved dosing precision compared to the vial version. OPUVIZ PFS aims to provide ophthalmologists with an additional option for managing retinal diseases effectively. The company has been offering OPUVIZ 40 mg/mL solution for injection in vials since May this year, and the product is also available in South Korea under the brand name AFILIVU™. Aflibercept, a vascular endothelial growth factor (VEGF) inhibitor, works by blocking abnormal blood vessel growth and leakage in the eye. OPUVIZ was first approved for treating various eye conditions, including wet age-related macular degeneration, macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation, by the European Commission in November 2024 and the Medicines and Healthcare products Regulatory Agency in April 2025.",
  "summary": "Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution in pre-filled syringe (PFS), a biosimilar referencing Eylea1(aflibercept), across Europe, starting today.“We are pleased to introduce the pre-filled syringe presentation of OPUVIZ to the European market, building on th",
  "key_points": [
    "Samsung Bioepis launches OPUVIZ™ 40 mg/mL pre-filled syringe in Europe.",
    "Vice President Antonio Rito praises convenience and precision of new format.",
    "OPUVIZ approved for wet AMD, macular edema, diabetic edema, and choroidal neovascularisation."
  ],
  "editors_take": "The launch of OPUVIZ in a pre-filled syringe format across Europe provides ophthalmologists with a more convenient and precise option for managing retinal diseases, potentially improving treatment outcomes.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}